On November 21, 2016, Amy E. Seibert, the controller and principal accounting officer of Surmodics, Inc. informed the company that she will resign from those positions. Ms. Seibert has agreed to continue in her position as controller through January 31, 2017. It is expected that Andrew D. C. LaFrence, the Company's current Vice President, Finance and Information Systems and Chief Financial Officer, and its principal financial officer, will be appointed to also serve as the Company's principal accounting officer, effective November 30, 2016. Mr. LaFrence, age 53, has been the Company's Vice President of Finance and Chief Financial Officer since February 2013, and prior to that, served as the chief financial officer for CNS Therapeutics.
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The Company's segments include Medical Device and IVD. The Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral, coronary and structural heart. It manufactures vascular intervention medical devices, including drug-coated balloons, and radial access balloon catheters and guide sheaths. The IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
SURMODICS, INC. 
